Scarica l'app Stockscreener
6.31
0.32%
-0.02
Dopo l'orario di chiusura:
6.31
Precedente Chiudi:
$6.33
Aprire:
$6.42
Volume 24 ore:
292.95K
Relative Volume:
0.88
Capitalizzazione di mercato:
$174.17M
Reddito:
$45.07M
Utile/perdita netta:
$-44.49M
Rapporto P/E:
-1.6981
EPS:
-3.716
Flusso di cassa netto:
$-54.23M
1 W Prestazione:
+1.45%
1M Prestazione:
-15.30%
6M Prestazione:
+8.42%
1 anno Prestazione:
+16.42%
Intervallo 1D:
$6.20
$6.44
Intervallo di 1 settimana:
$6.00
$6.47
Portata 52W:
$3.53
$9.62
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.31 | 171.68M | 45.07M | -44.49M | -54.23M | -3.716 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Iniziato | Guggenheim | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Ripresa | BTIG Research | Buy |
| 2020-04-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-05 | Iniziato | Stifel | Buy |
| 2020-02-25 | Iniziato | William Blair | Outperform |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-22 | Iniziato | Barclays | Overweight |
| 2019-04-22 | Iniziato | Goldman | Buy |
| 2019-04-22 | Iniziato | JP Morgan | Overweight |
| 2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Director Stanley Frankel Buys 1,000 Shares of Precision BioSciences (DTIL) - GuruFocus
At $6 per share, a director buys 1,000 Precision Biosciences (DTIL) shares - Stock Titan
Precision BioSciences, Inc. Revenue Breakdown – HAN:PBS0 - TradingView
Form 4 Precision BioSciences Inc For: 29 September By Investing.com - Investing.com Nigeria
Director Melinda Brown Buys 1,135 Shares of Precision BioSciences Inc (DTIL) - GuruFocus
Precision Biosciences director Melinda Brown buys $7,116 in stock By Investing.com - Investing.com Australia
Precision Biosciences director Geno Germano buys $16,384 in stock - Investing.com
Precision Biosciences director Melinda Brown buys $7,116 in stock - Investing.com
Precision Biosciences Director Geno J. Germano Acquires 2,609 Shares at $6.28 Each - kalkinemedia.com
At $6.27 a share, director Melinda Brown buys Precision BioSciences (DTIL) stock. - Stock Titan
A director buys Precision BioSciences (DTIL) shares at $6.28 each, bringing his direct holdings to 47,492. - Stock Titan
How Precision Biosciences Inc. (DTIL) Affects Rotational Strategy Timing - Stock Traders Daily
Precision BioSciences (DTIL) Short Interest & Short Float | Updated Sep 2026 $DTIL - MarketBeat
Precision Biosciences stock holds its Nasdaq listing - AD HOC NEWS
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to S&P Global BMI Index - marketscreener.com
Precision BioSciences stock trades quietly amid lack of fresh catalysts - AD HOC NEWS
Precision BioSciences Inc. (DTIL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Precision BioSciences at H.C. Wainwright conference: two shots on goal By Investing.com - Investing.com Canada
Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera - Barchart.com
Precision BioSciences, Inc. Share Price Live Today – NASDAQ:DTIL Stock Price, Chart, News, History - upstox.com
CPTx appoints Matt Kane as Chief Financial Officer - GlobeNewswire Inc.
Behavioral Patterns of DTIL and Institutional Flows - Stock Traders Daily
Precision BioSciences stock gains as market cap tops 200 million USD - ad-hoc-news.de
Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us
Precision BioSciences Inc. (DTIL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Precision BioSciences Inc. (DTIL) Peer Comparison – Compare with Others - Value Research
DTIL Q2 2026 Earnings: Wider-than-Expected Loss of $1.26 per Share Pressures StockWeak Earnings Momentum - dars.gov.et
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 - Business Wire
Precision BioSciences doses first patient in DMD gene editing trial By Investing.com - Investing.com Canada
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study - Yahoo Finance
Precision (DTIL) Momentum: Rises 1.61% to $8.86 in the Current Update; Chart View: the $8.42 to $9.30 Range Remains in Focus for the Current SessionGEX Level - careplusvn.com
Precision (DTIL) Range: Posts a 2.59% Gain to $8.72 at the Close; the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingLiquidity Order Flow - vinanet.vn
DTIL Looks 355.6% Overvalued on GF Value™ - GuruFocus
Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences Inc Stock Intrinsic Values - GuruFocus
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Competitors 2026 - GuruFocus
Precision BioSciences Inc Stock Warning Signs | HAM:PBS0 - GuruFocus
Who's Buying or Selling Precision BioSciences Inc (HAM:PBS0) Stock Today? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price & 30 Year Financial Data - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Earnings Transcripts - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
HAM:PBS0 Dividend: Does Precision BioSciences Inc Pay a Dividend? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price, Trades & News - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock News, Headlines & Updates - GuruFocus
Precision BioSciences (DTIL) Rises 1.78% as Gene-Editing Stock Holds Firm Above SupportGrowth Stock Picks - vinanet.vn
Precision BioSciences (DTIL) Advances 1.78% as Gene-Editing Speculation BuildsBear Flag - vinanet.vn
DTIL Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - careplusvn.com
DTIL Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Biotech ChallengesEPS Growth Report - dars.gov.et
Analysts Have Lowered Expectations For Precision BioSciences, Inc. (NASDAQ:DTIL) After Its Latest Results - webull.com
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Precision Biosciences Inc Azioni (DTIL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Brown Melinda | Director |
Sep 25 '26 |
Buy |
6.27 |
1,135 |
7,116 |
45,481 |
| Germano Geno J | Director |
Sep 25 '26 |
Buy |
6.28 |
2,609 |
16,385 |
47,492 |
| Amoroso Michael | President and CEO |
Feb 17 '26 |
Option Exercise |
0.00 |
67,797 |
0 |
263,951 |
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):